Matriptase 2 Polyclonal Antibody, FITC Conjugated
Applications
Reactivity
Predicted Reactivity
| Overview | |
| Catalog # | bs-8296R-FITC-100uL |
| Product Name | Matriptase 2 Polyclonal Antibody, FITC Conjugated |
| Applications |
WB
IF(IHC-P)
IF(IHC-F)
IF(ICC)
|
| Reactivity | Rat |
| Predicted Reactivity | Human, Mouse, Dog, Cow, Chicken |
| Specifications | |
| Conjugation | FITC |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human Matriptase 2 |
| Clonality | Polyclonal |
| Isotype | IgG |
| Concentration | 1ug/ul |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 164656 |
| Subcellular location | Cell membrane |
| Synonyms | Matriptase-2; Matriptase2; Membrane type serine proteinase 2; MTSP 2; MTSP2; PVAE354; TMPRSS 6; TMPRSS6; TMPS6_HUMAN; TMSP 6; TMSP6; Transmembrane protease serine 6; Type II Membrane Serine Proteinase 6. |
| Background | Serine protease which hydrolyzes a range of proteins including type I collagen, fibronectin and fibrinogen. Can also activate urokinase-type plasminogen activator with low efficiency. May play a specialized role in matrix remodeling processes in liver. Required to sense iron deficiency. Overexpression suppresses activation of the HAMP promoter.Involvement in disease:Defects in TMPRSS6 are the cause of iron-refractory iron deficiency anemia (IRIDA); also known as hypochromic microcytic anemia with defect in iron metabolism or hereditary iron-handling disorder or pseudo-iron-deficiency anemia. Key features include congenital hypochromic microcytic anemia, very low mean corpuscular erythrocyte volume, low transferrin saturation, abnormal iron absorption characterized by no hematologic improvement following treatment with oral iron, and abnormal iron utilization characterized by a sluggish, incomplete response to parenteral iron. |
| Application Dilution | |
| WB | 1:300-5000 |
| IF(IHC-P) | 1:50-200 |
| IF(IHC-F) | 1:50-200 |
| IF(ICC) | 1:50-200 |
Frequently asked questions
Which applications is Matriptase 2 Polyclonal Antibody, FITC Conjugated (bs-8296R-FITC) validated for, and at what dilution?
bs-8296R-FITC is validated for WB (1:300-5000); IF(IHC-P) (1:50-200); IF(IHC-F) (1:50-200); IF(ICC) (1:50-200). These are recommended starting dilutions; optimal dilutions should be determined by the end user.
Which species does Matriptase 2 Polyclonal Antibody, FITC Conjugated (bs-8296R-FITC) react with?
Tested reactivity: Rat. Predicted reactivity (expected from sequence homology but not yet tested): Human, Mouse, Dog, Cow, Chicken.
How should bs-8296R-FITC be stored?
Store at -20C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. Storage buffer: Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
What immunogen was used to raise Matriptase 2 Polyclonal Antibody, FITC Conjugated (bs-8296R-FITC)?
KLH conjugated synthetic peptide derived from human Matriptase 2
What are the excitation and emission wavelengths of the FITC conjugate (bs-8296R-FITC)?
FITC on bs-8296R-FITC: excitation / emission 494nm/518nm.